Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Prelude Therapeutics ( (PRLD) ) has issued an update.
Prelude Therapeutics reported its third-quarter 2025 financial results and provided a corporate update, highlighting advancements in its pipeline programs. The company is progressing with its JAK2V617F inhibitor and KAT6A degrader programs, with IND filings expected in 2026. Financially, Prelude reduced its net loss to $19.7 million compared to the previous year, with a cash runway projected into 2027, supported by recent license payments.
The most recent analyst rating on (PRLD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Underperform.
Prelude Therapeutics faces significant financial hurdles due to ongoing losses and lack of revenue, which heavily impact its overall score. Technical analysis shows mixed short-term momentum, but long-term weakness persists. The valuation is challenged by a negative P/E ratio and lack of dividends. However, recent corporate developments, including promising clinical results and a solid cash runway, offer some positive aspects, albeit insufficient to offset the broader financial concerns.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics is a precision oncology company focused on developing innovative medicines for cancer patients with high unmet needs. The company’s pipeline includes selective inhibitors and degraders targeting specific mutations and pathways in cancer cells.
Average Trading Volume: 1,284,315
Technical Sentiment Signal: Hold
Current Market Cap: $71.31M
For detailed information about PRLD stock, go to TipRanks’ Stock Analysis page.